Sun Pharmaceutical Industries Limited (BOM:524715)
India
· Delayed Price · Currency is INR | Market Cap | 4.29T |
| Revenue (ttm) | 516.03B |
| Net Income (ttm) | 114.34B |
| Shares Out | n/a |
| EPS (ttm) | 47.71 |
| PE Ratio | 37.54 |
| Forward PE | n/a |
| Dividend | 15.50 (0.87%) |
| Ex-Dividend Date | Feb 6, 2025 |
| Volume | 19,562 |
| Average Volume | 70,277 |
| Open | 1,757.20 |
| Previous Close | 1,747.25 |
| Day's Range | 1,742.85 - 1,792.00 |
| 52-Week Range | 1,376.75 - 1,960.20 |
| Beta | n/a |
| RSI | 60.55 |
| Earnings Date | May 22, 2025 |
About BOM:524715
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and othe... [Read more]
Financial Performance
In 2023, BOM:524715's revenue was 484.97 billion, an increase of 10.51% compared to the previous year's 438.86 billion. Earnings were 95.76 billion, an increase of 13.01%.
Financial StatementsNews
Nifty 50 top gainers today, April 17: Eternal, Sun Pharmaceutical, ICICI Bank, Bharti Airtel and more
The Indian equity market witnessed a robust rally on April 17, 2025, with benchmark indices closing significantly higher. The Nifty 50 surged by 414.45 points or 1.77%, ending the session at 23,851.65...
Glenmark, Sun & Zydus recall products in US for 'manufacturing deviations'
India News: NEW DELHI: Drug makers Glenmark, Sun Pharma and Zydus are recalling products in the US for manufacturing issues, the US Food and Drug Administration (.
Sun Pharma shares jump over 4% after US court clears LEQSELVI™ launch
Shares of Sun Pharmaceutical Industries Ltd. surged 4.29% to ₹1,723 in early trade on Friday after the company received a major legal win in the U.S. that removes barriers to the launch of its product...
Sun Pharma cleared to launch LEQSELVI™ in U.S. as court vacates injunction
Sun Pharmaceutical Industries has received a major legal boost in its U.S. operations after the U.S. Court of Appeals for the Federal Circuit ruled in its favor and vacated the preliminary injunction ...
Indian pharma stocks tumble as Trump signals tariffs on drug imports
Indian pharmaceutical stocks experienced a downturn following Donald Trump's renewed threat to impose tariffs on pharmaceutical imports. The Nifty Pharma index fell by 1.7%, with major companies like ...
Pharma Stocks Falls: Aurobindo Pharma slips 2%, Lupin down 2%, Divi’s Labs falls 3% as Trump reiterates tariffs on pharmaceuticals ‘soon’
Indian pharmaceutical stocks declined in early trade on Wednesday following renewed concerns over potential U.S. import tariffs. At 9:36 AM, Aurobindo Pharma shares were down 2% to ₹1,073.15, Dr. Redd...
Sun Pharma launches FEXUCLUE 40 mg in India for treatment of Erosive Esophagitis
Sun Pharmaceutical Industries Limited has announced the launch of FEXUCLUE® (Fexuprazan) 40 mg tablets in India, a novel treatment for Erosive Esophagitis. FEXUCLUE® is a Potassium-Competitive Acid Bl...
Sun Pharma shares fall over 4% today as tariff concerns resurface for pharma sector
Shares of Sun Pharmaceutical Industries Ltd fell 4.50% to ₹1,690.40 on Friday, declining ₹79.60 from the previous close of ₹1,770.00, after U.S. President Donald Trump announced that his administratio...
Nifty 50 top gainers today, April 3: Power Grid, Sun Pharmaceutical, Cipla, UltraTech and more
The Indian equity market witnessed a downturn on April 3, as both the Sensex and Nifty 50 closed in the red following the announcement of fresh U.S. tariffs. The benchmark Sensex dropped 322.08 points...
Sun Pharma shares rise over 5% as U.S. excludes Indian pharmaceutical exports from 26% tariff regime
Shares of Sun Pharmaceutical Industries Ltd surged 5.20% to ₹1,802.80 in early trade on April 3 after the White House confirmed that pharmaceutical products will not be subject to the 26% reciprocal t...
Sun Pharma, Dr. Reddy’s, Welspun India, Bharat Forge, Lupin, Biocon, UPL, Aurobindo, Indo Count, Cummins India and over 100 other Indian companies could face major impact from 26% US tariff hike
In a major escalation of trade tensions, US President Donald Trump on April 2 announced a 26% reciprocal tariff on imports from India, citing high tariffs imposed by India on American goods. The move ...
Pharma and healthcare stocks: Macquarie turns bullish on Sun Pharma, Cipla, Lupin; bearish on Apollo Hospitals, Max Healthcare
Macquarie believes the recent correction in pharmaceutical formulation stocks triggered by tariff-related concerns presents a compelling buying opportunity. In its latest sector note, the brokerage ha...
Nifty 50 top losers today, March 27: Tata Motors, Sun Pharmaceutical, Eicher Motors, Apollo Hospitals and more
The Indian equity markets continued their bullish momentum on March 27, with benchmark indices ending the trading session on a positive note. The Nifty 50 closed at 23,591.95, gaining 105.10 points (0...
Sun Pharma share price: HSBC sees 21% upside, maintains ‘Buy’; bullish on Checkpoint Therapeutics acquisition
HSBC has reiterated its ‘Buy’ rating on Sun Pharma, setting a target price of ₹2,000, indicating a 21% upside from the current market price of ₹1,657 (as of March 11). The brokerage remains optimistic...
Stock Market news: Bharti Airtel, Zydus Life, Bharat Forge, Tata Motors, Sun Pharma among stocks to watch today on brokerage updates
Several stocks are in focus today following fresh brokerage reports. Key updates include Bharti Airtel’s tie-up with SpaceX’s Starlink, Zydus Life’s acquisition of Amplitude Surgical, and varied views...
Nifty 50 top gainers today, March 11: Trent, BPCL, Sun Pharmaceutical, ICICI Bank and more
The Indian equity indices closed on a flat note in a volatile session on March 11, 2024. The BSE Sensex dipped marginally by 12.85 points or 0.02 percent to settle at 74,102.32, while the NSE Nifty 50...
Sun Pharma share price: Nomura maintains ‘neutral’ rating, sets target at Rs 1,970 amid Checkpoint Therapeutics acquisition
Nomura has maintained a ‘neutral’ rating on Sun Pharmaceutical Industries Ltd, setting a target price of ₹1,970 per share. The brokerage highlighted Sun Pharma’s announcement to acquire Checkpoint The...
Stocks to Watch Today: IndusInd Bank, BEL, Sun Pharma, SBI Cards, Maruti in focus on brokerage updates
Indian stock markets are expected to remain volatile today, with several key stocks under focus based on fresh brokerage updates. Analysts have revised ratings, target prices, and highlighted emerging...
Sun Pharma to acquire US oncology compony for over Rs 3,000 crore
Sun Pharma, India's largest pharmaceutical company, is set to acquire Checkpoint Therapeutics for $355 million. This strategic acquisition will enhance Sun Pharma's specialty portfolio, including UNLO...
Checkpoint Agrees To Sun Pharma Buyout: This Deal Suits Both Parties
Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn an additional $0.7 with the CVR.
M&A Snapshot: Sun Pharma to acquire Nasdaq-listed Checkpoint Therapeutics for $355M
India's Sun Pharma buys onco-derman firm Checkpoint Therapeutics for $355M
Stocks to watch today, March 10: Sun Pharma, ONGC, JSW Steel, Biocon, Omaxe and more
The Indian stock market has been experiencing significant movement, with the BSE Sensex rising by 1,134.48 points (1.55%) and the NSE Nifty gaining 427.8 points (1.93%) last week. However, today, Gift...
HSBC cuts target price for Sun Pharma shares by Rs 280 to Rs 2,000
HSBC has maintained its ‘Buy’ rating on Sun Pharma but has lowered the target price to ₹2,000 from ₹2,280. The brokerage remains optimistic about the company’s growth prospects, particularly in the sp...
Macquarie bullish on select pharma and CDMO stocks, bearish on hospitals
Macquarie believes that the recent correction in pharma stocks due to US tariff threats provides an attractive buying opportunity, particularly in formulations and CDMO (Contract Development and Manuf...